Geode Capital Management LLC Buys 291,124 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Geode Capital Management LLC lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 3.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 8,792,011 shares of the company’s stock after purchasing an additional 291,124 shares during the period. Geode Capital Management LLC owned about 0.78% of Teva Pharmaceutical Industries worth $157,571,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. UMB Bank n.a. lifted its holdings in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the period. Smithfield Trust Co lifted its stake in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the period. Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $52,000. Claro Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at $52,000. Finally, Mark Sheptoff Financial Planning LLC bought a new position in Teva Pharmaceutical Industries in the 2nd quarter worth $57,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.55% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TEVA. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays upped their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, UBS Group upped their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $16.50 on Tuesday. The company has a market capitalization of $18.69 billion, a price-to-earnings ratio of -19.48, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries Limited has a one year low of $10.00 and a one year high of $19.31. The company’s 50-day moving average is $17.49 and its 200 day moving average is $17.40.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.